Elite Athletes Diagnosed and Treated for Diabetes May Reduce Heart Failure

Published Date: 08 Mar 2023

95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.

Read Full News

Latest News

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD Henry Lim, MD

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

The Medical Sisterhood: Advocacy and Systemic Change, With Kristi Hawley, DO Mona Shahriari, MD, FAAD, Kristi B. Hawley, DO

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

Todays Updates

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Todays Updates

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Latest News

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

News All Time

Skin of Color Savvy: Highlights from 2025 Tim Smith

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

Skin of Color Savvy: On-Site Interviews at the Meeting the Challenge Summit Angel S. Byrd, MD, PhD, Valerie D. Callender, MD, Valerie Harvey, MD, MPH, Stafford Brown, MD, MBA

This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.

Skin of Color Savvy: Highlights From the Most-Watched Episodes of 2025 Andrew F Alexis, MD, MPH, Shawn Kwatra, MD, Crystal Aguh, MD, FAAD, John E. Harris, MD, PhD, Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Personalized Care Improvements Identified for Older Patients with Skin Cancer

What to Expect at the 2026 Maui Derm Conference

What to Expect at the 2026 Maui Derm Conference

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

Recommended News For You

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'

Making informed decisions and managing regret after prostate cancer treatment

New study highlights success of financial toxicity tumor board in reducing cancer treatment costs

Prostate cancer therapies: AI-based image analysis detects early organ damage

Recommended Articles For You

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options 

Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern  

The Latest Research on Chronic Granulomatous Disease and Promising New Treatments  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

2.

Researchers find distinct cell receptors with the potential for new treatments.

3.

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

4.

Second opinions don't significantly delay breast cancer treatment

5.

Year in Review: Chronic Lymphocytic Leukemia

1.

How Prevident is Revolutionizing Oral Care

2.

The Capmist DM: A Revolutionary Way to Combat Dry Mouth

3.

AI-Powered Rehabilitation: A Game Changer for Hemophilia Management

4.

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells

5.

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

2.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

4.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

5.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot